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TO THE EDITOR
We read with interest the article entitled
‘‘IGF-1 signalling controls the hair
growth cycle and the differentiation of
hair shafts’’ (Weger and Schlake, 2005).
Recently, we have reported docu-
mentation of the role of primary IGF-1
deficiency on hair structure in human
beings (Lurie et al., 2004). Laron
syndrome is a recessively inherited
disease of primary IGF-1 deficiency
owing to primary growth hormone
insensitivity. Affected children have
sparse hair growth and frontal reces-
sions. The hair is thin and easy to pluck,
and young adults have various degrees
of alopecia. Despite signs of early
aging, graying of the hair is delayed
and reduced (Laron, 2004). The syn-
drome is caused by deletions or muta-
tions in the growth hormone receptor or
postreceptor pathways, which lead to
an inability to generate IGF-1 (Laron,
2002, 2004). We investigated the effect
of primary IGF-1 deficiency on hair
structure by sampling the hair of 11
patients with Laron syndrome. The most
significant structured defect, pili torti et
canaliculi, was found in two young,
untreated patients. Grooving, tapered
hair, and trichorrhexis nodosa were
found in the remainder. IGF-1-treated
patients had either none or significantly
fewer pathological changes compared
to the untreated patients.
We believe our report (Lurie et al.,
2004) supplements that of Weger and
Schlake (2005) in demonstrating the
regulatory function of IGF-1 on hair
growth in man from a different direction.
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Whereas IGF-I has been initially de-
scribed as a potent mitogen supporting
cell growth and survival (Stewart and
Rotwein, 1996), there is accumulating
evidence for its participation in diverse
differentiation processes (Musaro and
Rosenthal, 1999; Hsieh et al., 2004).
Our recent work on IGF-I confirmed
this dual role for the murine hair follicle
(Weger and Schlake, 2005a, b). In man,
an IGF-I deficiency is associated with
Laron syndrome (Laron, 2002). Interest-
ingly, patients show impaired hair
production and structural abnormalities
of hair shafts (Lurie et al., 2004). On the
molecular level, people with Laron
syndrome are similar to Ivl::Igfbp3 mice
that are supposed to have reduced
levels of freely available IGF-I. The
suppression of endogenous signalling
in these mice causes a remarkable
thinning of hair shafts that has been
also described for Laron syndrome
(Lurie et al., 2004; Weger and Schlake,
2005b); by contrast, overexpression of
Igf-I appeared to increase murine hair
thickness (Weger and Schlake, 2005a).
However, other structural defects of
hair shafts were only observed in
Ivl::Igf-I mice (Weger and Schlake,
2005a); Ivl::Igfbp3 hair shafts looked
fairly normal as opposed to hair from
Laron syndrome patients (Lurie et al.,
2004; Weger and Schlake, 2005b). This
discrepancy between man and mouse
might be owing to several reasons:
firstly, it may point to a fundamental
difference between these species.
Actually, there is already precedence
for structural diversity; whereas the
murine hair shaft medulla forms easily
visible air spaces during differentia-
tion, they are lacking in human hair.
Secondly, it is possible that the
obtained suppression of IGF-I signalling
in Ivl::Igfbp3 mice is lower than in
people suffering from Laron syndrome.
However, data on mouse lines with
significantly different expression levels
of Igfbp3 suggest that effects are re-
stricted to quantitative alterations of
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hair length and thickness. Thirdly, the
primary defect giving rise to Laron
syndrome is a block of growth hormone
signalling (Laron, 2002). Thus, some
abnormalities might be not owing
to IGF-I deficiency. As growth factors
share many intracellular signalling
pathways, a partial compensation of
such defects by IGF-I treatment might
be possible. Consequently, interpreta-
tion of data on Laron syndrome has to
be very cautious with respect to IGF-I’s
role in human hair follicles. Although
similarities regarding IGF-I and hair
production are apparent between man
and mouse, a detailed comparative
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TO THE EDITOR
The erythrokeratodermas (EKs) include
a clinically and genetically heteroge-
neous group of disorders characterized
by erythematous and hyperkeratotic
lesions, either stationary or migratory.
Two major subtypes have been defined:
erythrokeratodermia variabilis (EKV,
OMIM 133200) and progressive sym-
metric erythrokeratodermia (PSEK,
OMIM 602036). PSEK is characterized
by fixed erythematous keratotic plaques
distributing symmetrically over the
body, particularly on the extremities,
the buttocks, and the faces, sometimes
together with palmoplantar keratoder-
ma. Two sisters have been described, in
which the younger one suffering EKV
whereas the older one suffering PSEK,
and this report brought forward the
hypothesis that PSEK and EKV were
different manifestations of a single
conditions (MacFarlane et al., 1991).
However, accumulating genetic studies
supported the distinct molecular
pathology underlying them (Richard
et al., 1998, 2002, 2003). The major
clinical feature distinguishing between
PSEK and EKV is the sharply outlined
geographical regions of migratory
erythema in the latter (Ishida-Yamamo-
to et al., 1997), and parakeratosis
is an evident pathological feature in
PSEK and usually not seen in
EKV. Furthermore, ichthyotic variant
of Vohwinkel syndrome, KID syn-
drome, and some transgradient forms
of palmoplantar keratoderma should
also be differentiated from PSEK based
on the clinical and histological char-
acteristics.
The pathologic mechanism of PSEK
is still unknown. No loci for PSEK have
been defined by genetic linkage anal-
ysis up to date. A frameshift mutation
(709insC) in the loricrin gene (OMIM
#152445) on chromosome 1q21 has
been identified in a Japanese PSEK
family with generalized, well-demar-
cated erythematous hyperkeratotic
plaques and mutilating palmoplantar
keratoderma (pseudoainhum) (Ishida-
Yamamoto et al., 1997). Loricrin is a
major structural component of the
crosslinked cell envelope of the epider-
mis, which participates in the formation
of keratohyalin granules (Hohl et al.,
1991; Candi et al., 1995), and the
responsibility of the loricrin gene for
variant form of Vohwinkel syndrome
has been demonstrated (Maestrini et al.,
1996). Some authors considered the
Japanese pedigree mentioned above
affecting variant form of Vohwinkel
syndrome rather than PSEK, because
pseudoainhum was usually not seen in
PSEK, and the location of above muta-
tion was only 21 bp upstream to that of
Vohwinkel syndrome variant form
(730insG) (Richard et al., 2002). Our
previous study has excluded the loricrin
gene is the responsibility gene for PSEK
(Cui et al., 2004).
To map the disease locus of PSEK,
we carried out a genome-wide scan in a
five-generation Chinese PSEK family
consisting of 27 individuals. There are
12 affected individuals in this family,
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A Locus for Progressive Symmetric Erythrokeratodermia
